Uremic pruritus is a debilitating symptom frequently encountered in individuals with chronic kidney disease (CKD), particularly those receiving haemodialysis. This condition, characterised by ...

Preliminary trial findings suggest transdermal cannabis may help ease pruritus-related itching in patients undergoing hemodialysis. Cannabis cream relieved itching symptoms over the short-term in a ...

Please provide your email address to receive an email when new articles are posted on . The National Kidney Foundation recently hosted a live event, as a part of its NKF Live series, to discuss uremic ...

Cara Therapeutics is developing an oral formulation for pruritus associated with various conditions after FDA-approved intravenous difelikefalin for ESRD patients. Although the primary endpoint was ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc. ("Trevi") today announced the closing of a $10 million Series A financing to advance the clinical development of T111 in the lead indication ...

Difelikefalin, an investigational intravenous (IV) drug for treating itch (pruritus) in patients with end-stage renal disease on hemodialysis, was safe and effective in two parallel pivotal trials in ...

Investors propelled shares of Cara Therapeutics Inc. (NASDAQ:CARA) to a one-year high Thursday after the company reported top-line results from the phase II trial of lead kappa opioid agonist CR845, ...

Work at Escient Pharmaceuticals Inc. has led to the discovery of novel Mas-related G protein-coupled receptor member X4 (MRGPRX4) antagonists as potential therapeutic candidates for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . Hemodiafiltration may allow more effective toxin removal vs. high-flux hemodialysis. Hemodiafiltration was ...